These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26075843)

  • 21. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Minamisawa M; Claggett B; Suzuki K; Hegde SM; Shah AM; Desai AS; Lewis EF; Shah SJ; Sweitzer NK; Fang JC; Anand IS; O'Meara E; Rouleau JL; Pitt B; Pfeffer MA; Solomon SD; Vardeny O
    Circ Heart Fail; 2021 Nov; 14(11):e008293. PubMed ID: 34674539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
    Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
    Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
    Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
    Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
    Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).
    Huynh T; Harty BJ; Claggett B; Fleg JL; McKinlay SM; Anand IS; Lewis EF; Joseph J; Desai AS; Sweitzer NK; EileenO'Meara ; Pitt B; Pfeffer MA; Rouleau JL
    Am J Cardiol; 2019 Feb; 123(4):611-617. PubMed ID: 30612727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The frailty syndrome and outcomes in the TOPCAT trial.
    Sanders NA; Supiano MA; Lewis EF; Liu J; Claggett B; Pfeffer MA; Desai AS; Sweitzer NK; Solomon SD; Fang JC
    Eur J Heart Fail; 2018 Nov; 20(11):1570-1577. PubMed ID: 30225878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT.
    Barkoudah E; Claggett BL; Lewis EF; O'Meara E; Clausell N; Diaz R; Fleg JL; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    J Card Fail; 2022 Sep; 28(9):1390-1397. PubMed ID: 35636727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spironolactone in chronic hemodialysis patients improves cardiac function.
    Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
    Onarecker C
    J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
    Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
    J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
    Vizzardi E; Nodari S; Caretta G; D'Aloia A; Pezzali N; Faden G; Lombardi C; Raddino R; Metra M; Dei Cas L
    Am J Med Sci; 2014 Apr; 347(4):271-6. PubMed ID: 24196866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
    Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
    J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
    Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
    Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
    Lund LH; Ståhlberg M
    JAMA; 2013 Jul; 310(2):205. PubMed ID: 23839758
    [No Abstract]   [Full Text] [Related]  

  • 40. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
    Milan A; Abram S; Veglio F
    JAMA; 2013 Jul; 310(2):204-5. PubMed ID: 23839757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.